Skip to content

PT-141 (Bremelanotide) Results: Timeline, Before & After & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Results Timelines

0 to 30 minutes post-injection:

  • Peptide enters systemic circulation and begins receptor binding
  • Mild injection site warmth or redness may occur
  • Nausea, if it occurs, typically begins within this window

30 to 60 minutes:

  • Peak plasma concentration reached
  • Initial onset of effects reported by many users
  • Flushing and warmth may become apparent

1 to 4 hours:

  • Maximal therapeutic window
  • Effects on desire, arousal, and genital sensitivity are most pronounced
  • Blood pressure elevation peaks between 2 to 4 hours post-dose

4 to 8 hours:

  • Therapeutic effects gradually diminish
  • Despite a plasma half-life of approximately 2.7 hours (range 1.9 to 4.0 hours), biological effects on sexual function persist for 6 to 8 hours in clinical observations, likely reflecting receptor residence time and downstream neurochemical changes

8 to 12 hours:

  • Blood pressure and heart rate return to baseline
  • Systemic clearance is essentially complete within 8 to 10 hours
  • 64.8% is excreted in urine and 22.8% in feces

Individual response varies. Some users report effects within 15 to 20 minutes, while others require up to 90 minutes for onset. The prescribing information advises patients to determine their own optimal timing through experience.

Frequently Asked Questions

PT-141 reaches peak plasma concentration within 30 to 60 minutes of subcutaneous injection. Most users experience onset of effects within 45 minutes, with maximal therapeutic benefit occurring 2 to 4 hours post-dose. Effects may persist for 6 to 8 hours.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
  2. Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917.
  3. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-38.
  4. Safarinejad MR. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008;179(3):1066-71.
  5. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
  6. Simon JA, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(1):61-68.
  7. U.S. Food and Drug Administration. Vyleesi (bremelanotide injection) prescribing information. NDA 210557. 2019.
  8. Dhillon S. Bremelanotide: first approval. Drugs. 2019;79(14):1599-1606.
  9. Palatin Technologies. FDA approves new drug application for Vyleesi (bremelanotide injection). Press release. June 21, 2019.
  10. World Anti-Doping Agency. The 2026 Prohibited List. WADA.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”